Taken together, these data support the hypothesis that TRPC4/C5 represent novel and safe non-opioid targets for the treatment of several pain conditions, in addition to attenuating suffering, depression, and anxiety associated with chronic pain. This evidence concerns the gene TRPC4 and depressive disorder.